HK1243346A1 - 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 - Google Patents

在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 Download PDF

Info

Publication number
HK1243346A1
HK1243346A1 HK18102930.9A HK18102930A HK1243346A1 HK 1243346 A1 HK1243346 A1 HK 1243346A1 HK 18102930 A HK18102930 A HK 18102930A HK 1243346 A1 HK1243346 A1 HK 1243346A1
Authority
HK
Hong Kong
Prior art keywords
bendamustine
volume
subject
less
administered
Prior art date
Application number
HK18102930.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯瑞坎斯．孙达拉姆
斯瑞坎斯．孫達拉姆
斯考特．L．塔瑞弗
Original Assignee
赛多斯有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1243346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 赛多斯有限责任公司 filed Critical 赛多斯有限责任公司
Publication of HK1243346A1 publication Critical patent/HK1243346A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HK18102930.9A 2012-03-20 2018-02-28 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 HK1243346A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US61/613,173 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US61/669,889 2012-07-10
US201261678715P 2012-08-02 2012-08-02
US61/678,715 2012-08-02

Publications (1)

Publication Number Publication Date
HK1243346A1 true HK1243346A1 (zh) 2018-07-13

Family

ID=49212373

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102930.9A HK1243346A1 (zh) 2012-03-20 2018-02-28 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法

Country Status (17)

Country Link
US (3) US9000021B2 (enExample)
EP (3) EP2827863B1 (enExample)
JP (6) JP6224064B2 (enExample)
CN (2) CN107157988A (enExample)
CA (1) CA2867343C (enExample)
DK (2) DK2827863T3 (enExample)
ES (2) ES2718902T3 (enExample)
FI (1) FI3533447T3 (enExample)
HK (1) HK1243346A1 (enExample)
HR (2) HRP20230276T1 (enExample)
HU (2) HUE062230T2 (enExample)
LT (1) LT2827863T (enExample)
PL (2) PL3533447T3 (enExample)
PT (2) PT3533447T (enExample)
RS (2) RS64137B1 (enExample)
SI (2) SI3533447T1 (enExample)
WO (1) WO2013142359A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HRP20230276T1 (hr) * 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
EP3836921B1 (en) 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
WO2021014957A1 (ja) * 2019-07-22 2021-01-28 富士フイルム株式会社 ベンダムスチン注射液製剤
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AU706890B2 (en) 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
ES2373864T3 (es) 1998-04-20 2012-02-09 Eisai R&D Management Co., Ltd. Composición estabilizada que contiene un compuesto de tipo bencimidazol.
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
KR20080039954A (ko) * 2005-08-31 2008-05-07 오노 야꾸힝 고교 가부시키가이샤 점적용 주사제
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
KR20110110293A (ko) 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
CN101584668A (zh) * 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
CN107353342B (zh) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2864118A1 (en) 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni

Also Published As

Publication number Publication date
ES2718902T3 (es) 2019-07-05
JP6224064B2 (ja) 2017-11-01
EP2827863B1 (en) 2019-01-16
US20150343061A1 (en) 2015-12-03
EP2827863A4 (en) 2015-11-18
SI2827863T1 (sl) 2019-06-28
HRP20230276T1 (hr) 2023-04-28
JP2022028813A (ja) 2022-02-16
US9000021B2 (en) 2015-04-07
JP6381761B2 (ja) 2018-08-29
RS58744B1 (sr) 2019-06-28
PT3533447T (pt) 2023-05-17
HUE062230T2 (hu) 2023-10-28
EP3533447B1 (en) 2023-03-15
CA2867343C (en) 2020-08-11
DK3533447T3 (da) 2023-04-24
US9579384B2 (en) 2017-02-28
CN104271135B (zh) 2017-05-17
LT2827863T (lt) 2019-06-10
CN107157988A (zh) 2017-09-15
EP2827863A1 (en) 2015-01-28
JP2024037915A (ja) 2024-03-19
US20130253026A1 (en) 2013-09-26
CN104271135A (zh) 2015-01-07
JP6738376B2 (ja) 2020-08-12
JP2020143143A (ja) 2020-09-10
HRP20190693T1 (hr) 2019-10-04
PL3533447T3 (pl) 2023-07-17
RS64137B1 (sr) 2023-05-31
SI3533447T1 (sl) 2023-06-30
CA2867343A1 (en) 2013-09-26
JP2018197248A (ja) 2018-12-13
PT2827863T (pt) 2019-05-13
EP4218756A1 (en) 2023-08-02
HUE044233T2 (hu) 2019-10-28
PL2827863T3 (pl) 2019-07-31
WO2013142359A1 (en) 2013-09-26
ES2943668T3 (es) 2023-06-15
DK2827863T3 (en) 2019-04-23
FI3533447T3 (fi) 2023-05-04
EP3533447A1 (en) 2019-09-04
US20150080444A1 (en) 2015-03-19
JP2018048153A (ja) 2018-03-29
JP2015510940A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
CN104271135B (zh) 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
JP7133070B2 (ja) ベンダムスチンの製剤
CN102006875A (zh) 吡铂和贝伐单抗治疗结直肠癌的用途
HK40097690A (en) Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40013204A (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40013204B (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40109505A (en) Formulations of bendamustine
CN103561745A (zh) 用于治疗癌症的药剂和方法